Poly Medicure Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Poly Medicure Ltd filed with BSE on 29 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Poly Medicure reported FY26 standalone revenue of around Rs 1,662 crore, up about 4%, and consolidated revenue of Rs 1,875 crore, up 12.3%, with standalone EBITDA margin of 26.8%. Management described FY26 as a year of transition toward high-technology segments, including the acquisitions of PendraCare, Citieffe, and Medyneo in Brazil. The company guided FY27 consolidated revenue of Rs 2,300-2,400 crore and standalone revenue of Rs 1,900-1,950 crore, while flagging raw material cost pressure and Gulf-region shipping disruptions.
Numbers mentioned
Standalone revenue: INR1,662 crores (FY26)
p. 4
“the stand-alone revenue was around INR1,662 crores, which was up by around 4% compared to previous year”
Himanshu Baid, page 4 of the filed PDF · View the filing
Standalone gross margin: 68.1% (FY26)
p. 4
“Gross margin expanded by around 128 bps and was up to around 68.1% from last year's 66.8% or something like that”
Himanshu Baid, page 4 of the filed PDF · View the filing
Standalone EBITDA margin: 26.8% (FY26)
p. 4
“We have delivered close to 26.8% at the higher end of the range and stand-alone EBITDA was INR446 crores”
Himanshu Baid, page 4 of the filed PDF · View the filing
Standalone revenue: INR443 crores (Q4 FY26)
p. 4
“Stand-alone revenue for the quarter 4 was INR443 crores up 5.2% year-on-year, 6% sequentially, it was highest ever stand-alone quarter”
Himanshu Baid, page 4 of the filed PDF · View the filing
Q4 EBITDA margin: 27.3% (Q4 FY26)
p. 4
“with a healthy margin of 27.3%”
Himanshu Baid, page 4 of the filed PDF · View the filing
Consolidated revenue: INR1,875 crores (FY26)
p. 5
“on the consolidated picture, full year consolidated revenue grew by 12.3% to INR1,875 crores, domestic business was around 20%, international was about 9% year-on-year”
Himanshu Baid, page 5 of the filed PDF · View the filing
Q4 consolidated revenue: INR534 crores (Q4 FY26)
p. 5
“Q4 consolidated revenue was INR534 crores, up around 21% year-on-year basis with a gross profit of INR356 crores and 66.7% margin”
Himanshu Baid, page 5 of the filed PDF · View the filing
Q4 consolidated EBITDA: INR112 crores (Q4 FY26)
p. 5
“Q4 consolidated EBITDA were INR112 crores, a little lower than the stand-alone numbers because there was an impact of consolidation of low-margin acquisitions and about INR9 crores onetime regulatory and cost provisions in one of our international subsidiaries”
Himanshu Baid, page 5 of the filed PDF · View the filing
Infusion Therapy revenue share: 50% (Q4 FY26)
p. 5
“Infusion Therapy now accounts for 50% of the revenue, down from 57% in Q4 '25 with Renal around 11%”
Himanshu Baid, page 5 of the filed PDF · View the filing
Consolidated cash: INR842 crores
p. 5
“consolidated cash of around INR842 crores”
Himanshu Baid, page 5 of the filed PDF · View the filing
FY26 capex: INR296 crores (FY26)
p. 5
“For FY '26, the capex was around INR296 crores pertaining to our plants Haridwar, Faridabad, Mitrol and also in YEIDA Medical Park”
Himanshu Baid, page 5 of the filed PDF · View the filing
Dialysis machines placed: around 450 machines (FY26)
p. 4
“On the Renal platform, we have placed around 450 dialysis machines last year, taking our installed capacity to approximately 1,000 machines”
Himanshu Baid, page 4 of the filed PDF · View the filing
Stents deployed: close to 11,000 (FY26)
p. 4
“On Cardiology, now we deployed close to 11,000 stents”
Himanshu Baid, page 4 of the filed PDF · View the filing
Citieffe/PendraCare revenue: INR65 crores (Q4 FY26)
p. 11
“the total revenue of INR65 crores that we have done from the 2 acquisitions, about INR43 crores, INR44 crores is from Citieffe and the balance is from PendraCare”
Rahul Gautam, page 11 of the filed PDF · View the filing
Citieffe calendar year revenue: EUR17.5 million (CY25)
p. 16
“Deepak, for Citieffe, that number was about EUR17.5 million. And for PendraCare, it was about EUR8 million”
Rahul Gautam, page 16 of the filed PDF · View the filing
Capacity utilization post QIP-1: 65% to 70%
p. 14
“after the QIP-1 we are seeing a capacity utilization of close to around 65% to 70% right now”
Himanshu Baid, page 14 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Consolidated revenue — INR2,300 crores to INR2,400 crores · FY27
stated firmly by Himanshu Baid
p. 6
“we are guiding a revenue of INR2,300 crores to INR2,400 crores, up from INR1,875 crores we have done in FY '26, which will include full year consolidation of PendraCare and Citieffe”
Himanshu Baid, page 6 of the filed PDF · View the filing
Standalone revenue — INR1,900 crores to INR1,950 crores · FY27
stated firmly by Himanshu Baid
p. 6
“On stand-alone basis, we are guiding on a revenue of INR1,900 crores to INR1950 crores with domestic business growing upwards of 20% and international business growing upwards of 15%”
Himanshu Baid, page 6 of the filed PDF · View the filing
Standalone EBITDA margin — 25% to 27% · FY27
stated firmly by Himanshu Baid
p. 6
“Stand-alone EBITDA margin is expected to be -- again, we are giving a guidance of 25% to 27% range”
Himanshu Baid, page 6 of the filed PDF · View the filing
Consolidated EBITDA margin — 23% to 25% · FY27
stated firmly by Himanshu Baid
p. 7
“we expect this year consolidated EBITDA to be between 23% and 25%, but stand-alone will be between 25% and 27%”
Himanshu Baid, page 7 of the filed PDF · View the filing
Capex — INR200 crores to INR225 crores · FY27
stated firmly by Himanshu Baid
p. 7
“We expect to spend between INR200 crores to INR225 crores on capex this year”
Himanshu Baid, page 7 of the filed PDF · View the filing
Gross margin erosion — 66% to 68%, lower by 200-300 bps
stated conditionally by Himanshu Baid
p. 6
“we may see some erosion on gross margin going from, let's say, 68% to maybe around 66% or maybe in that region, maybe lower by 200 bps, 300 bps”
Himanshu Baid, page 6 of the filed PDF · View the filing
Renal segment growth — over 20% · FY27
stated firmly by Himanshu Baid
p. 8
“we are still seeing maybe a 20% growth or maybe over 20% growth this year also in this business”
Himanshu Baid, page 8 of the filed PDF · View the filing
Citieffe growth (euro terms) — 10% to 12% · FY27
stated firmly by Rahul Gautam
p. 16
“In euro terms, I think we should be growing for Citieffe in low double digit, about 10% to 12%”
Rahul Gautam, page 16 of the filed PDF · View the filing
PendraCare/Citieffe EBITDA margin — around 18% to 20% · next 2-3 years
stated as an aspiration by Himanshu Baid
p. 18
“currently, these companies will operate, let's say, around 12% to 14% margin. That is what we anticipate. But I think in next 2, 3 years, we could see that improvement to going to around 18% to 20%”
Himanshu Baid, page 18 of the filed PDF · View the filing
India:international revenue mix — 1/3 India, 2/3 rest of world · long term
stated as an aspiration by Himanshu Baid
p. 11
“So it's a great question. So ideally, I would like it to be between like 1/3 India and 2/3 RoW.”
Himanshu Baid, page 11 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said it was a small acquisition, about $40,000, that fast-tracks regulatory approvals in Brazil.
Answered by Rahul Gautam
Asked by Sidharth Negandhi: Details on the Brazil acquisition, its revenue and cost.
p. 8
“From an acquisition standpoint, it was about $40,000. So it's a small acquisition from a cash outlay perspective, but it clearly saves us anywhere between 18 to 24 months to be able to operationalize the business.”
Rahul Gautam, page 8 of the filed PDF · View the filing
Management said domestic competition is absent but Chinese imports remain a headwind, still targeting over 20% growth.
Answered by Himanshu Baid
Asked by Shamit Ashar: What growth is projected in the Renal segment given Chinese competition?
p. 8
“we are still seeing maybe a 20% growth or maybe over 20% growth this year also in this business. We have initiated certain actions against Chinese companies.”
Himanshu Baid, page 8 of the filed PDF · View the filing
Management said currently yes but noted uncertainty about future developments.
Answered by Himanshu Baid
Asked by Kanishk Gupta: Is the worst behind the company?
p. 10
“I can say that absolutely for the moment, yes, but we don't know what can happen tomorrow.”
Himanshu Baid, page 10 of the filed PDF · View the filing
Management confirmed core export revenue was negative for the quarter, around minus 3-4%.
Answered by Himanshu Baid
Asked by Neel Mehta: How does export growth look excluding PendraCare and Citieffe revenue?
p. 12
“Export, in fact, were negative, not flattish also. We were, I think, minus 3% or 4% on the export side.”
Himanshu Baid, page 12 of the filed PDF · View the filing
Management said the acquisitions had a negative EBITDA impact this quarter due to seasonality and product mix, with medium-term margin targets higher.
Answered by Rahul Gautam
Asked by Neel Mehta: What is the EBITDA margin for PendraCare and Citieffe this quarter?
p. 13
“the acquisition has had a negative impact on EBITDA of about INR2.6 crores.”
Rahul Gautam, page 13 of the filed PDF · View the filing
Management attributed the Q4 dip to product mix rather than any structural change.
Answered by Rahul Gautam
Asked by Deepak: Why did gross margin dip in Q4 versus the first nine months?
p. 15
“the quarter 4 impact is primarily because of product mix issue.”
Rahul Gautam, page 15 of the filed PDF · View the filing
Management said dumping continues due to duty structure disadvantages but the company can still mitigate it via scale.
Answered by Himanshu Baid
Asked by Deepak: Has Chinese dumping in Renal eased given the strong quarterly growth?
p. 15
“Chinese dumping continues. I think there is no -- unless until government thinks otherwise, the dumping continues.”
Himanshu Baid, page 15 of the filed PDF · View the filing
Management said Infusion will likely remain around 50% of revenue as it is core, even as high-value segments grow.
Answered by Himanshu Baid
Asked by Girish Jain: Will Infusion's share of revenue keep declining as new segments grow?
p. 17
“we think that it will stay around that 50% level infusion because that's where Polymed today, if you see one of the products we manufacture, IV catheter, we have almost global 11% market share on that product”
Himanshu Baid, page 17 of the filed PDF · View the filing
Risks flagged
Raw material and plastic packaging cost increases linked to crude oil prices
p. 6
“we see there was an impact of around 20% on an aggregate basis in raw materials and a meaningful headwind to the gross margin”
Himanshu Baid, page 6 of the filed PDF · View the filing
Logistics and shipping disruption from the Gulf war affecting West Asia exports
p. 5
“I think it's a logistics nightmare right now. And I think there's a bottlenecks which are causing some disruption in shipping products out of India.”
Himanshu Baid, page 5 of the filed PDF · View the filing
Freight cost increases and minimum wage revision in Haryana
p. 6
“the freight cost and minimum wage revision in Haryana has caused some disruption”
Himanshu Baid, page 6 of the filed PDF · View the filing
Chinese dumping and cost inversion in the Renal segment due to import duty structure
p. 15
“today, Chinese are importing at 0% duty, only 5% GST pay on the finished product, whereas I'm importing -- I'm buying all the raw materials, I'm importing some raw materials, I pay 18% duty, I pay 2.5% duty custom duty on my raw materials, 18% GST”
Himanshu Baid, page 15 of the filed PDF · View the filing
Extended receivables cycle due to international customer support during difficult environment
p. 12
“there has been a significant jump on the debtor side, and that's primarily because of the external factors”
Rahul Gautam, page 12 of the filed PDF · View the filing
PendraCare exposure to Middle East region impacting margins
p. 13
“for PendraCare, they had a fairly large exposure to Middle East compared to what the overall group level is, which has gotten impacted a bit more”
Rahul Gautam, page 13 of the filed PDF · View the filing
Cancelled Latam tender affecting Citieffe revenue
p. 17
“it was primarily because of one of the tenders that they had been won in the Latam region was cancelled and was pushed out and because of which they lost a certain revenue in last calendar year”
Rahul Gautam, page 17 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.